Omada Health (NASDAQ:OMDA) Price Target Cut to $22.00 by Analysts at Canaccord Genuity Group

Omada Health (NASDAQ:OMDA) had its price target trimmed by Canaccord Genuity Group from $28.00 to $22.00 in a report released on Friday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other brokerages also recently issued reports on OMDA. Needham & Company LLC reissued a “buy” rating and set a $28.00 target price on shares of Omada Health in a research note on Thursday, January 22nd. BMO Capital Markets decreased their target price on Omada Health from $27.00 to $18.00 and set an “outperform” rating for the company in a research report on Friday. Morgan Stanley lowered their price target on Omada Health from $32.00 to $30.00 and set an “overweight” rating on the stock in a report on Friday. Wells Fargo & Company started coverage on Omada Health in a research report on Thursday, January 8th. They set an “equal weight” rating and a $17.00 price target on the stock. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Omada Health in a research report on Thursday, January 22nd. Eight equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $22.90.

Omada Health Stock Up 3.3%

Shares of Omada Health stock traded up $0.45 during trading on Friday, hitting $14.05. The stock had a trading volume of 5,381,314 shares, compared to its average volume of 1,317,712. Omada Health has a 1 year low of $10.28 and a 1 year high of $28.40. The stock has a 50 day simple moving average of $14.03 and a 200 day simple moving average of $18.68. The company has a market capitalization of $813.64 million and a PE ratio of -56.20.

Omada Health (NASDAQ:OMDA) last issued its quarterly earnings results on Thursday, March 5th. The company reported $0.08 EPS for the quarter, beating the consensus estimate of ($0.04) by $0.12. The firm had revenue of $75.85 million during the quarter.

Insider Activity

In other news, President Wei-Li Shao sold 5,618 shares of the firm’s stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $16.13, for a total transaction of $90,618.34. Following the completion of the sale, the president directly owned 69,079 shares of the company’s stock, valued at $1,114,244.27. This trade represents a 7.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Sean P. Duffy sold 230,479 shares of the firm’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $15.60, for a total value of $3,595,472.40. Following the sale, the chief executive officer directly owned 126,644 shares of the company’s stock, valued at $1,975,646.40. This trade represents a 64.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 276,893 shares of company stock worth $4,336,787.

Hedge Funds Weigh In On Omada Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Quarry LP acquired a new stake in Omada Health in the fourth quarter valued at approximately $29,000. TD Waterhouse Canada Inc. acquired a new position in shares of Omada Health during the 4th quarter worth $32,000. Raymond James Financial Inc. acquired a new position in shares of Omada Health during the 2nd quarter worth $32,000. Strs Ohio bought a new position in shares of Omada Health during the 3rd quarter valued at $38,000. Finally, Inlight Wealth Management LLC acquired a new stake in shares of Omada Health in the 4th quarter valued at $45,000.

Omada Health News Summary

Here are the key news stories impacting Omada Health this week:

• Positive Sentiment: Q4 results beat consensus — Omada reported $0.08 EPS vs. a ($0.04) consensus and $75.85M revenue, with year-over-year revenue growth and positive adjusted EBITDA and Q4 net income, signaling improving profitability. GlobeNewswire: Q4 & Full-Year Results
• Positive Sentiment: Company set a 2026 revenue-growth target (~22%) and is expanding its care offerings (new GLP-1 and cholesterol programs), which underpin upside to recurring revenue and member monetization. Seeking Alpha: 22% Growth Target & New Programs
• Positive Sentiment: Product launch — Omada announced “GLP‑1 Flex Care,” a program that enables employer-sponsored access to GLP‑1 obesity care while limiting employer drug-cost exposure, which could broaden sales channels and employer uptake. GlobeNewswire: GLP-1 Flex Care
• Positive Sentiment: Goldman Sachs maintained a Buy rating with a $26 target, citing a profitability inflection and double-digit growth outlook — a supportive institutional endorsement. TipRanks: Goldman Sachs Note
• Neutral Sentiment: Morgan Stanley trimmed its price target slightly (from $32 to $30) but kept an Overweight rating — still implies significant upside, so the impact is muted. Benzinga: Morgan Stanley PT
• Negative Sentiment: Several firms cut price targets — Canaccord lowered its target to $22 (still Buy), BMO cut to $18 (Outperform), and Barclays reduced its target to $17 — these cuts can create downward pressure despite bullish ratings. Benzinga: Canaccord / BMO notes TickerReport AmericanBankingNews: Barclays

About Omada Health

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.